Masimo (MASI) Stock

Masimo (MASI) has a strong track record of surprising with its earnings and currently has the right factors in place for a potential positive outcome in its upcoming quarterly report.

Is Masimo (MASI) a strong choice for momentum investors? Let's explore this question.

Szyman is currently the global president of Advanced Patient Monitoring at Becton Dickinson and Company.

On Tuesday, Masimo announced that it has appointed Katie Szyman, an executive from Becton Dickinson, as its new CEO. This decision follows a tough proxy fight with the activist hedge fund Politan Capital Management, which resulted in the removal of founder Joe Kiani from the company's board last year.

MASI's revenue growth in the fourth quarter probably increased due to the strong ongoing use of its products.

UPPSALA, SWEDEN / ACCESSWIRE / January 13, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) Senzime AB (publ.), a leader in patient monitoring technology, has announced that it has achieved a second milestone in its partnership with Masimo by integrating with the Masimo Iris® Gateway.

Leading analysts on Wall Street have updated their opinions on these major companies. To see all the changes in analyst ratings, including both upgrades and downgrades, visit our analyst ratings page.

MASI, PEN, and VCYT from the Zacks Medical Instruments sector are good investment options due to their use of genAI, strategic growth, and solid financial health. However, challenges like geopolitical tensions and problems with wages and supplies could affect their future performance.

MASI, PEN, and VCYT from the Zacks Medical Instruments sector are good investment options due to their use of genAI, strategic growth, and solid financial health. However, challenges like geopolitical tensions and problems with wages and supplies could affect their future performance.